



# TAVR-in-TAVR: the NEXT Challenging Issue in Lifetime TAVR Management

### Philippe Garot, MD

Interventional and structural cardiologist Institut cardiovasculaire Paris Sud (ICPS) Massy, France p.garot@angio-icps.com





#### **Disclosure**

Nature of Financial Relationship

Grant/Research Support

Consultant Fees/Honoraria

Individual Stock(s)/Stock Options

Royalties/Patent Beneficiary

**Executive Role/Ownership Interest** 

Other Financial Benefit

**Ineligible Company** 

none

Abbott, Biosensors, Boston

Scientific, Cordis, Edwards

Lifesciences, General Electric

Healthcare, Terumo

CERC (Cardiovascular

**European Research Center)** 

none


none


none





### **Background**








THVs are expected to fail






#### Considerations

- Optimal index TAVR procedure/ optimize outcomes and durability
- Planning for the future: coronary access and treatment options in case of THV failure










### Planning for the future

#### Redo TAVI faisable





#### Redo TAVI non faisable








TCTAP2024


### THV design/combination





### Implant depth and Neoskirt

#### **Neoskirt and Functional Neoskirt**












### **Implant depth and Neoskirt**







"Reasonably" high implant









# Planning for the future











# Commissural alignment





### Planning for the future

FIGURE 4 Factors Impacting the Risk of Coronary Obstruction and Coronary Access Impairment After Redo-TAVR PREDICTING RISK OF CORONARY OBSTRUCTION FOLLOWING REDO-TAVR Redo procedure Index procedure **Commissural alignment** Index THV design Implant depth of index THV **Expansion of index THV** Redo-TAVR THV choice S3 in Evolut **Evolut in Evolut** High implant Low implant I The neoskirt height can vary If the outflow of the index THV The index failed THV may I Redo-TAVR with a short frame Commissural alignment of across different THV designs. extends above the STJ or the I both the index THV and redo expand following redo-TAVR THV in a tall frame valve can The neoskirt height is higher in THV to STJ distance is <2mm, TAVR can help avoid coronary and this should be considered reduce the potential neoskirt valves where the leaflets are in obstruction and facilitate there is the potential for when determining and mitigate the risk of I a supra annular position. coronary obstruction. If the leaflet modification technique measurements for coronary I coronary obstruction I index THV was implanted I such as BASILICA. obstruction risk such as the lower avoiding the STJ then VTC distance. this mitigates the risk of obstruction





### Mr L. 82 YO

Evolut R 26mm 2018 BVD regurgitation

6 Yrs








VTC RCA & LM <4mm



### redoTAVI plan

**BASILICA?** 



**Low implant** 





# Neoskirt and leaflet overhang





TABLE 1 Neoskirt Height and Leaflet Overhang With Variable Implant Depth				
Evolut R	Sapien 3	Implant Depth (S3 Outflow)	Neoskirt Height, mm	Leaflet Overhang, %
23 mm	20 mm	Node 4	16.3	90
		Node 5	20.7	32
		Node 6	23.9	0
26 mm	23 mm	Node 4	17.1	90
		Node 5	21.0	49
		Node 6	23.4	9




Different degrees of Leaflet overhang





### Plan for RedoTAVI



### What did we do?









# Follow-up CT










### RedoTAV App available\*











### Take-home message

- Optimizing the index procedure
- Planning for the future before the index TAVR: THV design/implant depth/commissural alignment
- Tailored approach
- More clinical data is needed



